

TABLE 1—REGISTRATION REVIEW INTERIM DECISIONS BEING ISSUED—Continued

Registration review case name and number	Docket ID number	Chemical review manager and contact information
Dried Fermentation Solids and Solubles of <i>Myrothecium verrucaria</i> , Case 6051. EPTC, Case 0064 .....	EPA-HQ-OPP-2013-0539.	Cody Kendrick, <i>kendrick.cody@epa.gov</i> , (703) 347-0468
Ethylene, Case 3071 .....	EPA-HQ-OPP-2012-0720.	Patricia Biggio, <i>biggio.patricia@epa.gov</i> , (703) 347-0547
Fludioxonil, Case 7017 .....	EPA-HQ-OPP-2009-0877.	Susanne Cerrelli, <i>cerrelli.susanne@epa.gov</i> , (703) 308-8077
Formic Acid, Case 6073 .....	EPA-HQ-OPP-2010-1067.	Patricia Biggio, <i>biggio.patricia@epa.gov</i> , (703) 347-0547
Methyl Nonyl Ketone, Case 3094 .....	EPA-HQ-OPP-2014-0105.	Cody Kendrick, <i>kendrick.cody@epa.gov</i> , (703) 347-0468
Niclosamide, Case 2455 .....	EPA-HQ-OPP-2012-0125.	Daniel Schoeff, <i>schoeff.daniel@epa.gov</i> , (703) 347-0143
N <sup>6</sup> -Benzyladenine, Case 2040 .....	EPA-HQ-OPP-2013-0137.	R. David Jones, <i>jones.rdavid@epa.gov</i> , (703) 305-6725
Potassium Silicate, Case 6204 .....	EPA-HQ-OPP-2011-0190.	Alexandra Boukedes, <i>boukedes.alexandra@epa.gov</i> , (703) 347-0305
Propamocarb hydrochloride, Case 3124 .....	EPA-HQ-OPP-2017-0329.	Donna Kamarei, <i>kamarei.donna@epa.gov</i> , (703) 347-0443
Putrescent Whole Egg Solids, Case 4079 .....	EPA-HQ-OPP-2011-0662.	Christina Scheltema, <i>scheltema.christina@epa.gov</i> , (703) 308-2201
Sodium carbonate, Case 4066 .....	EPA-HQ-OPP-2010-0726.	Susanne Cerrelli, <i>cerrelli.susanne@epa.gov</i> , (703) 308-8077
TFM, Case 3082 .....	EPA-HQ-OPP-2012-0809.	SanYvette Williams, <i>williams.sanyvette@epa.gov</i> , (703) 305-7702
	EPA-HQ-OPP-2013-0137.	R. David Jones, <i>jones.rdavid@epa.gov</i> , (703) 305-6725

The proposed interim registration review decisions for the chemicals in the table above were posted to the docket and the public was invited to submit any comments or new information. EPA addressed the comments or information received during the 60-day comment period for the proposed interim decisions in the discussion for each pesticide listed in the table. Comments from the 60-day comment period that were received may or may not have affected the Agency's interim decision. Pursuant to 40 CFR 155.58(c), the registration review case docket for the chemicals listed in the Table will remain open until all actions required in the interim decision have been completed.

This document also announces the closure of the registration review case for Bis (bromoacetoxy)-2-butene (BBAB) (Case 3030, Docket ID Number EPA-HQ-OPP-2014-0799), because the last U.S. registrations for these pesticides have been canceled. Background on the registration review program is provided at: <http://www.epa.gov/pesticide-reevaluation>.

**Authority:** 7 U.S.C. 136 *et seq.*

Dated: October 25, 2018.

**Yu-Ting Guilaran,**

*Director, Pesticide Re-Evaluation Division,  
Office of Pesticide Programs.*

[FR Doc. 2018-26354 Filed 12-3-18; 8:45 am]

**BILLING CODE 6560-50-P**

## FEDERAL RESERVE SYSTEM

### Formations of, Acquisitions by, and Mergers of Bank Holding Companies

The companies listed in this notice have applied to the Board for approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 *et seq.*) (BHC Act), Regulation Y (12 CFR part 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below.

The applications listed below, as well as other related filings required by the Board, are available for immediate inspection at the Federal Reserve Bank indicated. The applications will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act (12 U.S.C. 1843). Unless otherwise noted, nonbanking activities will be conducted throughout the United States.

Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than December 31, 2018.

A. Federal Reserve Bank of Atlanta (Kathryn Haney, Assistant Vice President) 1000 Peachtree Street NE, Atlanta, Georgia 30309. Comments can also be sent electronically to [Applications.Comments@atl.frb.org](mailto:Applications.Comments@atl.frb.org):  
1. *B.P.C. Corporation, Cookeville, Tennessee*; to merge with CFB Bancshares, Inc., and thereby indirectly acquire Citizens First Bank, both of Wartburg, Tennessee.

Board of Governors of the Federal Reserve System, November 29, 2018.

**Yao-Chin Chao,**

*Assistant Secretary of the Board.*

[FR Doc. 2018-26328 Filed 12-3-18; 8:45 am]

**BILLING CODE P**

## GENERAL SERVICES ADMINISTRATION

[Notice-MA-2018-10; Docket No. 2018-0002; Sequence No. 28]

### Relocation Allowances: Taxes on Travel, Transportation, and Relocation Expenses

**AGENCY:** Office of Government-wide Policy (OGP), General Services Administration (GSA).

**ACTION:** Notice of Federal Travel Regulation (FTR) Bulletin 19–02, Relocation Allowances—Taxes on Travel, Transportation, and Relocation Expenses.

**SUMMARY:** The purpose of this notice is to inform Federal agencies that FTR Bulletin 19–02, pertaining to travel, transportation, and relocation allowances impacted by recent changes to Federal tax law, has been published and is now available online at [www.gsa.gov/ftrbulletin](http://www.gsa.gov/ftrbulletin).

**DATES:** *Applicability:* This notice applies to travel, transportation, and relocation expenses paid on or after January 1, 2018.

**FOR FURTHER INFORMATION CONTACT:** For clarification of content, please contact Mr. Rick Miller, Office of Government-wide Policy, Office of Asset and Transportation Management, at 202–501–3822, or by email at [travelpolicy@gsa.gov](mailto:travelpolicy@gsa.gov). Please cite Notice of FTR Bulletin 19–02.

Dated: November 27, 2018.

**Jessica Salmoiraghi,**  
Associate Administrator, Office of  
Government-wide Policy.

[FR Doc. 2018–26342 Filed 12–3–18; 8:45 am]

BILLING CODE 6820–14–P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Agency for Healthcare Research and Quality

#### Supplemental Evidence and Data Request on Interventions for Substance Use Disorders in Adolescents: A Systematic Review

**AGENCY:** Agency for Healthcare Research and Quality (AHRQ), HHS.

**ACTION:** Request for supplemental evidence and data submissions.

**SUMMARY:** The Agency for Healthcare Research and Quality (AHRQ) is seeking scientific information submissions from the public. Scientific information is being solicited to inform our review of *Interventions for Substance Use Disorders in Adolescents: A Systematic Review*, which is currently being conducted by the AHRQ's Evidence-based Practice Centers (EPC) Program. Access to published and unpublished pertinent scientific information will improve the quality of this review.

**DATES:** *Submission Deadline* on or before January 3, 2019.

**ADDRESSES:** *Email submissions:* [epc@ahrq.hhs.gov](mailto:epc@ahrq.hhs.gov).

*Print submissions:*

*Mailing Address:* Center for Evidence and Practice Improvement, Agency for Healthcare Research and Quality, ATTN: EPC SEADs Coordinator, 5600 Fishers Lane, Mail Stop 06E53A, Rockville, MD 20857.

*Shipping Address (FedEx, UPS, etc.):* Center for Evidence and Practice Improvement, Agency for Healthcare Research and Quality, ATTN: EPC SEADs Coordinator, 5600 Fishers Lane, Mail Stop 06E77D, Rockville, MD 20857.

**FOR FURTHER INFORMATION CONTACT:** Jenae Bennis, Telephone: 301–427–1496 or Email: [epc@ahrq.hhs.gov](mailto:epc@ahrq.hhs.gov).

**SUPPLEMENTARY INFORMATION:** The Agency for Healthcare Research and Quality has commissioned the Evidence-based Practice Centers (EPC) Program to complete a review of the evidence for *Interventions for Substance Use Disorders in Adolescents: A Systematic Review*. AHRQ is conducting this systematic review pursuant to Section 902(a) of the Public Health Service Act, 42 U.S.C. 299a(a).

The EPC Program is dedicated to identifying as many studies as possible that are relevant to the questions for each of its reviews. In order to do so, we are supplementing the usual manual and electronic database searches of the literature by requesting information from the public (e.g., details of studies conducted). We are looking for studies that report on *Interventions for Substance Use Disorders in Adolescents: A Systematic Review*, including those that describe adverse events. The entire research protocol, including the key questions, is also available online at: <https://effectivehealthcare.ahrq.gov/topics/substance-use-disorders-adolescents/protocol>.

This is to notify the public that the EPC Program would find the following information on *Interventions for Substance Use Disorders in Adolescents: A Systematic Review* helpful:

- A list of completed studies that your organization has sponsored for this indication. In the list, please *indicate whether results are available on ClinicalTrials.gov along with the ClinicalTrials.gov trial number.*

- *For completed studies that do not have results on ClinicalTrials.gov, please provide a summary, including the following elements: study number, study period, design, methodology, indication and diagnosis, proper use instructions, inclusion and exclusion criteria, primary and secondary outcomes, baseline characteristics, number of patients screened/eligible/*

enrolled/lost to follow-up/withdrawn/analyzed, effectiveness/efficacy, and safety results.

- *A list of ongoing studies that your organization has sponsored for this indication.* In the list, please provide the *ClinicalTrials.gov* trial number or, if the trial is not registered, the protocol for the study including a study number, the study period, design, methodology, indication and diagnosis, proper use instructions, inclusion and exclusion criteria, and primary and secondary outcomes.

- Description of whether the above studies constitute ALL Phase II and above clinical trials sponsored by your organization for this indication and an index outlining the relevant information in each submitted file.

Your contribution will be very beneficial to the EPC Program. Materials submitted must be publicly available or able to be made public. Materials that are considered confidential; marketing materials; study types not included in the review; or information on indications not included in the review cannot be used by the EPC Program. This is a voluntary request for information, and all costs for complying with this request must be borne by the submitter.

The draft of this review will be posted on AHRQ's EPC Program website and available for public comment for a period of 4 weeks. If you would like to be notified when the draft is posted, please sign up for the email list at: <https://www.effectivehealthcare.ahrq.gov/email-updates>.

*The systematic review will answer the following questions. This information is provided as background. AHRQ is not requesting that the public provide answers to these questions.*

#### The Key Questions

**KQ 1:** What are the effects of behavioral, pharmacologic, and combined interventions compared with placebo or no active treatment for substance use disorders and problematic substance use<sup>1</sup> in adolescents to achieve abstinence, reduce quantity and frequency of use, improve functional outcomes, and reduce substance-related harms?

a. How do benefits and adverse outcomes of interventions vary by subpopulations?<sup>2</sup>

<sup>1</sup> Substances considered: Alcohol, cannabis, opioids, sedatives/hypnotics/anxiolytics, stimulants, inhalants and hallucinogens. Tobacco is excluded.

<sup>2</sup> Subpopulations considered: Psychiatric comorbidities, age (early, middle and late